CURRICULUM VITAE
John R. Harvey, M.D.
Oklahoma Cardiovascular Associates 4050 W. Memorial Rd., Third Floor Oklahoma City, Oklahoma 73120
(405)608-3800 Phone (405)608-3838 Fax Curriculum Vitae John R. Harvey, M.D.
BUSINESS ADDRESS: Oklahoma Cardiovascular Associates 4050 W. Memorial Rd, Third Floor Oklahoma City, Oklahoma 73120 405-608-3800
Oklahoma Foundation for Cardiovascular Research (OFCR) Oklahoma Cardiovascular Research Group (OCRG) 4200 W. Memorial Rd, Suite 510 Oklahoma City, Oklahoma, 73120 405-608-1280
OFCR/OCRG 4050 W. Memorial Rd., 3rd Floor Oklahoma City, Oklahoma 73120 PERSONAL DATA:
Date of Birth: March 18, 1955
Place of Birth: Oklahoma City, Oklahoma
Citizenship: United States of America
EDUCATION: Premedical: Oklahoma Baptist University Oklahoma City, OK 74801 Degree: Bachelor of Science 1974-1977
Medical: University of Oklahoma College of Medicine Oklahoma City, Oklahoma Degree: Doctor of Medicine 1977-1981
POSTGRADUATE EDUCATION:
Internship: Internal Medicine University of Oklahoma Health Sciences Center Oklahoma City, OK 73190 July 1981 - June 1982
Rev: 4/29/2018 Page 2 of 14 Curriculum Vitae John R. Harvey, M.D.
Residency: Internal Medicine University of Oklahoma Health Sciences Center Oklahoma City, OK 73190 July 1982 - June 1984
Fellow: Cardiology University of Oklahoma Health Sciences Center Oklahoma City, OK 73190 July 1984 - June 1987
Interventional Cardiology Harvard University Beth Israel Hospital Boston, MA July 1987 - June 1988
BOARD CERTIFICATIONS: National Board of Medical Examiners July 1982
American Board of Internal Medicine Internal Medicine 1984-2050
Cardiovascular Disease American Board of Internal Medicine 1987-2050
Interventional Cardiology American Board of Internal Medicine 1999-12/31/2009
LICENSURE: STATE NUMBER ISSUE EXPIRES Oklahoma 13766 07/01/2010 DEA: US 10/31/2012 BNDD: OK 16777 10/31/2010
MALPRACTICE INSURANCE POLICY: PLICO 609272 07/01/2004 1/1/2010 Address: P.O. Box 26727 Oklahoma City, Oklahoma 73156-0727 405-290-5660 Phone 405-290-5709 Fax
HOSPITAL AFFILIATIONS: Holdenville General Hospital Valley View Regional Hospital Mercy Health Center
Rev: 4/29/2018 Page 3 of 14 Curriculum Vitae John R. Harvey, M.D. Oklahoma Heart Hospital
PROFESSIONAL MEMBERSHIPS: Oklahoma State Medical Association Associate, American College of Physicians American Heart Association Fellow, American College of Cardiology
PROFESSIONAL REFERENCES: Dwayne A. Schmidt, M.D. 4050 W. Memorial Road Third Floor Oklahoma City, Oklahoma 73120 405 608-3800
Ronald H. White, M.D. 4050 W. Memorial Road Third Floor Oklahoma City, Oklahoma 73120 405 608-3800
Mark Fixley, M.D. 4050 W. Memorial Road Third Floor Oklahoma City, Oklahoma 73120 405 608-3800
PROFESSIONAL EXPERIENCE: Chief Executive Officer Oklahoma Heart Hospital 2006 - Present
Interventional & Clinical Cardiologist Oklahoma Cardiovascular Associates 4050 W. Memorial Road Third Floor Oklahoma City, OK 73120 December 1998 - Present
Oklahoma Foundation for Cardiovascular Research (OFCR) 711 Stanton L Young Blvd, #100 Oklahoma City, OK 73104 Director 1993 - Present President 1993 - 1994 President 2003 - Present
Medical Director Oklahoma Heart Hospital 4050 W. Memorial Road Oklahoma City, Oklahoma 73120 July 2002 - Present
Rev: 4/29/2018 Page 4 of 14 Curriculum Vitae John R. Harvey, M.D. Chairman of the Board Oklahoma Heart Hospital 4050 W. Memorial Road Oklahoma City, Oklahoma 73120 July 2002 - Present
Interventional & Clinical Cardiologist Heart Group of Oklahoma 1000 N. Lincoln Suite 400 Oklahoma City, OK 73104 November 1991 - November 1998
Director of Interventional Cardiology, Oklahoma Memorial Hospital July 1988 - October 1991
ADMINISTRATIVE COMMITTEE ACTIVITY: Attending Physician, VA Medical Center Oklahoma City, OK 1986
Director of Interventional Cardiology, Oklahoma Memorial Hospital 1988
Presbyterian Hospital Oklahoma City, OK 1989 - 2002
COMMITTEE ACTIVITY, EDUCATION:
January 2003 OFCR GCP Training Information
Attending Physician, VA Medical Center, Cardiac Catheterization Laboratory 1986
Clinical Instructor, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 1986
Assistant Professor, Department of Medicine University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma 1988
CLINICAL INVESTIGATIONS:
Paradoxical embolism Aortic and Mitral Valvuloplasty PTCA restenosis
Rev: 4/29/2018 Page 5 of 14 Curriculum Vitae John R. Harvey, M.D. A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alniditan (0.4, 0.8 or 1.4 mg) Given Subcutaneously in the Acute Treatment of Migraine. Janssen ALN-INT-17
Open Evaluation of the Long Term Efficacy, Safety and Tolerability of 1.4 mg SC Alniditan in the Acute Treatment of Migraine Attacks. Janssen ALN-USA-18
Dilation Versus Ablation Revascularization Trial (DART) Targeting Restenosis. Boston Scientific.
Multicenter, Randomized, Parallel, Double-Blind Study to Investigate the Safety and Clinical Efficacy of MK383 in Combination with Heparin versus Heparin Alone in Patients with High- Risk Unstable Angina/Non-Q-Wave Myocardial Infarction. Merck 383-006-06
Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients with Non-Insulin Dependent Diabetes Mellitus and Nephropathy. Merck 147
Stent Antithrombotic Regimen Study (STARS) Johnson and Johnson.
Dose Finding Study of Efegatran Sulfate Versus Heparin in Patients with Acute Myocardial Infarction. Eli Lilly (PRIME) H3M-MC-EQAC(b) Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study of the Chronic
Administration of Vesnarinone in Heart Failure. Otsuka 22-94-201
Open Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure. Otsuka 22-95-209
Phase III, Randomized, Double-Blind, Placebo Controlled Evaluation of the Acute and Chronic Efficacy and Safety of OPC18790 in the Treatment of Patients With Decompensated Heart Failure. Otsuka 103-93-203
Phase III, Randomized, Double-Blind, Long Term Continuation Study of OPC18790 in Patients with Decompensated Heart Failure. Otsuka 103-93-204
Multicenter, Randomized 2-arm Trial: AngioJet Rheolytic Thrombectomy Versus Intracoronary/Graft Urokinase Thrombolysis. Vein Graft AngioJet Study. Possis, Inc. VeGas II
Beta Blocker Evaluation of Survival Trial (BEST). NHLB-VA CSP#395. NIH
"AFFIRM: Atrial Fibrillation Follow Up Investigation of Rhythm Management". NIH
A Long Term Safety and Efficacy Trial of BMS-180048 in the Treatment of Acute Migraine Attacks. Bristol-Myers Squibb CN115-030-047
Open Label, Long-Term Trial Evaluating the Safety of BMS-180048 150 mg in the Treatment of Patients With or Without Aura. Bristol-Myers Squibb CN115-038-005
A Double-Blind, Randomized Trial of BMS-180048, Ergotamine Tartrate Plus Caffeine and Placebo in the Treatment of Migraine in Patients with Risk of Coronary Artery Disease. Bristol-Myers Squibb CN115-032-001
Rev: 4/29/2018 Page 6 of 14 Curriculum Vitae John R. Harvey, M.D.
Study of the Safety and the Pharmacodynamic Effects of SR 33589B Administered Orally for One Month to Patients with Left Ventricular Dysfunction. Sanofi-Winthrop ACT2401
Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of 30, 40 and 50 mg Orbofiban Administered Twice Daily and 50 mg Orbofiban Administered Once Daily in Patients with Stabilized Ischemic Syndrome. Searle I59-96-02-011
Assessment of Treatment With Lisinopril and Survival. Zenica ATLAS
A Dose Response Study of the Safety and Efficacy of Diltiazem Once Daily Extended Release in the Treatment of Chronic Stable Exercise-Induced Angina Pectoris. BioVail HR 1321A/8/USA/301/AP
The Effectiveness and Safety of Subcutaneous Enoxaparin Compared to Intravenous Unfractionated Heparin for Patients Presenting With Unstable Angina or Non-Q-Wave MI: A Double-Blind, Randomized, Parallel Group, Multicenter Study. Rhone Poulenc 54563-303. ESSENCE
Multicenter, Double-Blind, Randomized, Parallel, Captopril-Controlled Study to Investigate the Safety and Tolerability of Losartan in Elderly Patients With Symptomatic Heart Failure. Merck (ELITE) MK-954 No. 097-00
Randomized, Double-Blind, Placebo-Controlled Study of the Effects of MK-383 on Cardiac Outcomes in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA) or Atherectomy Due to Unstable Angina Pectoris or Following Acute Myocardial Infarction. Merck MK383-013-03
Multicenter, Open Label, Clinical Trial to Assess the Long-Term Safety of 75 mg of Azimilide Dihydrochloride in Patients with Atrial Fibrillation/Flutter and/or Paroxysmal Supraventricular Tachycardia. Proctor and Gamble 1995116
FDP-201. “A Dose-Ranging Study of FDP on Hemodynamics in Patients with Decompensated Heart Failure.”
Assessment of Cardioversion Using Transesophageal Echocardiography: the Acute Study. NHLBI. NIH
A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of MK-0462 Compared to Sumatriptan on Coronary Artery Dimension and on Systemic and Pulmonary Hemodynamics in Patients with Mild Coronary Artery Disease. O34-00. Merck & Co., Inc.
A Multicenter, Double-Blind, Placebo Controlled Study of the Cardiovascular Safety and Tolerability of MK-462 in Otherwise Healthy Migraineurs. 020-01. Merck & Co., Inc.
A Randomized, Placebo-Controlled, Dose-Titration Study of CS-866 with Long-Term Safety Evaluation in Patients with Essential Hypertension. 866-306. Sankyo USA Corp.
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). NIHTU
Rev: 4/29/2018 Page 7 of 14 Curriculum Vitae John R. Harvey, M.D.
A Multicenter, Open-Label Clinical Trial to Assess the Long-Term Safety of a Daily Oral Dose of 125mg of Azimilide Dihydrochloride in Patients with Atrial Fibrillation/Flutter and/or Paroxysmal Supraventricular Tachycardia. #1998018. Proctor & Gamble Pharmaceuticals, Inc.
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy; US LIFE, Losartan. #133-00. Merck & Co., Inc.
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Trial to Assess the Effect of Valsartan on Exercise Capacity, Quality of Life, and Signs and Symptoms, in Patients with Stable, Chronic Congestive Heart Failure (NYHA Class II-IV). CGP48933-106. Novartis Pharmaceutical Company
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Carvedilol on Mortality in Patients with Severe Chronic Heart Failure. MF4477/SB287. COPERNICUS STUDY. SmithKline Beecham Pharmaceuticals
Placebo-Controlled Study of Omapatrilat in Subjects with Isolated Systolic Hypertension. CV137-042-089. Bristol-Myers Squibb Pharmaceutical Research Institute
The Efficacy and Safety of Omapatrilat Added to Hydrochlorothiazide for the Treatment of Hypertension in Subjects Non-Responsive to Hydrochlorothiazide Alone. CV137-040-063. Bristol-Myers Squibb Pharmaceutical Research Institute
Placebo-Controlled Study of Omapatrilat in Elderly Subjects with Mild to Moderate Hypertension. CV137-029. Bristol-Myers Squibb Pharmaceutical Research Institute
A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Active Controlled Trial in Patients with Essential Hypertension to Compare the Effect of Valsartan 80 and 160mg, with or without the Addition of Hydrochlorothiazide, Once Daily to that of Amlodipine 5 and 10mg Once Daily, with or without the Addition of Hydrochlorothiazide, on Cardiovascular Morbidity and Mortality. Protocol 405, Ver:22 July 1997. Novartis Pharmaceuticals
A Phase II, Randomized, Open-Label, Crossover, Multicenter, Multidose Study of the Safety, Pharmocokinetics, and Pharmacodynamics of DMP 754 (Roxifiban) in Combination with Aspirin in Patients with Coronary Artery Disease. DMP 754-017. DuPont Pharmaceutical Company
A Phase II, Randomized, Double-Blind, Multicenter, Acetylsalicylic Acid-Controlled, Multi- Dose Study of DMP 754 Alone or in Combination with Aspirin in Patients with Coronary Artery Disease. DMP 754-010-085. DuPont Pharmaceutical Company
The 2nd Symphony Trial: A Phase III, Multicenter, International, Randomized, Double-Blind, Aspirin-Controlled Trial to Evaluate the Efficacy and Safety of Two Regimens with Xubix™
(Sibrafiban; RO 48-3657), An Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonist, As Therapy for the Long Term Prevention of Secondary Vascular Events in Patients After An Acute Coronary Syndrome. BC15457. Hoffmann-La Roche Ltd.
Efficacy and Safety of Xemilofiban Hydrochlorothiazide (SC 54684 A) Administration to Patients Undergoing Coronary Angioplasty or Stent Placement: Pivotal Trial. IF7-96-02-017.
Rev: 4/29/2018 Page 8 of 14 Curriculum Vitae John R. Harvey, M.D. Excite. G.D. Searle & Company
A Randomized, Double-Blind, Aspirin-Controlled Study with Two Dose Regimens of Sibrafiban (RO 48-3657), An Oral Platelet Glycoprotein IIb/IIIa Antagonist, in Patients After Acute Coronary Syndrome (Unstable Angina, Q-Wave or Non-Q Wave MI). BC15574. Hoffmann-La Roche Ltd.
A Single-Blind Randomized Study of the Safety and Effectiveness of Percutaneous Transluminal Myocardial Revascularization (PTMR) Performed with Eclipse Holmium Laser as an Adjunct to Percutaneous Coronary Intervention in Patients Selected to Receive Percutaneous Coronary Intervention. TMR-012A. Eclipse Surgical Technologies
A Single-Blind Randomized Study of the Safety and Effectiveness of Percutaneous Transluminal Myocardial Revascularization (PTMR) Performed with the Eclipse Holmium Laser in Patients with a Coronary Artery Chronic Total Occlusion. TMR-012B. Eclipse Surgical Technologies
Linezolid (PNU-100766) in the Treatment of Patients with Nosocomial Pneumonia: A Double- Blind, Randomized, Comparator-Controlled Study. M/1260/0048. Pharmacia & Upjohn
Linezolid (PNU-100766) in the Treatment of Streptococcus Pneumoniae Pneumonia: An Open- Label Study of Intravenously Administered Linezolid with Oral Continuation Compared with Intravenously Administered Ceftriazone Sodium Followed by Orally Administered Cefpodoxime Proxetil. M/1260/0033. Pharmacia & Upjohn
A Double-Blind, Placebo-Controlled, Multinational Trial to Investigate the Effect of the Na+/H+ Exchange Inhibitor HOE642 (Cariporide) on All-Cause Mortality and Myocardial Infarction in Patients at Risk of Myocardial Necrosis Due to Acute Coronary Syndrome Related to the Disease Process or to an Interventional Cardiac Procedure. HOE642A/3001. Hoechst Marion Roussel
Multicenter, Randomized, Open-Label, Active-Controlled, Dose Titration, Efficacy, and Safety Study of OPC-41061 in Hospitalized Patients with Hyponatremia. 156-97-204. Otsuka America Pharmaceuticals
The Effect of Sustained-Release Moxonidine on Morbidity in Patients with Congestive Heart Failure. B3N-MC-EUBC (a)/773. Eli Lilly
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients with Non-Insulin Dependent Diabetes Mellitus and Nephropathy. #147. RENAAL. Merck & Co., Inc.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tedisamil in the Maintenance of Sinus Rhythm Following Cardioversion in Patients with Chronic Persistent Atrial Fibrillation. #S2192101. Solvay Pharmaceuticals
A Multicenter, Open-Label, Randomized Trial Comparing Clinical Outcome with Hirulog andProvisional Abciximab versus Planned Abciximab and Low-Dose Heparin in Patients Undergoing Percutaneous Intervention. #TMC-97-02. Innovex/Duke/Quintile
A Double-Blind, Randomized trial of Clodipogrel 300 mg Loading Dose & Aspirin 325 mg. Followed by Clodipogrel 75 mg & Aspirin daily compared with placebo loading dose & Aspirin 325 mg followed by Clodipogrel 75 mg & Aspirin daily for the prevention of Vascular events and
Rev: 4/29/2018 Page 9 of 14 Curriculum Vitae John R. Harvey, M.D. all-cause mortality in patients undergoing percutaneous coronary Intervention. Bristol-Myers Squibb CREDO
Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion. BRAVO
Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure. COMPANION
Double Blind, Placebo Controlled Study of the Efficacy and Safety of BMS 207940, A Selective Endothelin A Receptor Antagonist, In Subjects with Intermittent Claudication. BMS PVD
A phase III Multi-center Randomized Double Blind Placebo Controlled Pilot Trial Evaluating the Effects of Infliximab (Remicade) in Patients with Class III or IV Congestive Heart Failure. ATTACH
The Vascular Filtration System Trial Protocol”. TRAP
Prospective, Randomized, Single-Blinded, Parallel-Group (Two Arm), Multicenter, Clinical Evaluation of the RX Achieve™ Drug-Coated Coronary Stent System in the Treatment of the Patients with De Novo Native Coronary Artery Lesions DELIVER 1/24/01
A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCL vs. Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I) TAKEDA 520 8/9/01 - C
Protocol Number 276, April 26, 2001: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial to Evaluate the Effect of Extended Release Metoprolol Succinate (Toprol- XL®) on Cardiac Remodeling in Asymptomatic Heart Failure Patients (NYHA Class I) With Left Ventricular Dysfunction REVERT 1/28/02 - 3/2/04
A Prospective, Multicenter, Non-Randomized, Registry Study to Evaluate the Safety and Efficacy of the Medtronic AVE S8 Coronary Stent System in Subjects with DeNovo and Restenotic Lesions of the Native Coronary Arteries AVE S8 2/27/02 - 11/24/03
A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS). Aventis Pharmaceuticals Protocol Number ENO.GMA.301 SYNERGY 9/21/02
Randomized Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure REVIVE 2/17/02 - 4/13/05
ONTARGET: Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial: A large, simple, randomized trial of an angiotensin II receptor antagonist (telmisartan) and an ace-inhibitor (ramipril) in patients at high risk for cardiovascular events, and including a parallel study, TRANSCEND: Telmisartan Randomized Assessment Study in Ace-Inhibitor Intolerant Subjects with Cardiovascular Disease 10/21/01
Prospective, Randomized, Single-Blinded, Parallel-Group(two-arm), Multi-Center, Clinical Evaluation of the RX ACHIEVE Drug Coated Coronary Stent System (CSS) in the treatment of Patients with DeNovo Native Coronary Artery Lesions DELIVER 1/24/01
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the
Rev: 4/29/2018 Page 10 of 14 Curriculum Vitae John R. Harvey, M.D. Safety and Efficacy of BO-653 in Prevention of Post-Angioplast Restenosis in Stented Lesions PREVAIL 2/22/02 - 10/20/04
A prospective, randomized trial evaluating the TAXUS Paclitaxel – Eluting Coronary Stent in De Novo Coronary Lesions and In-Stent Restenosis TAXUS IV 3/15/02
A 6-week, Open-Label, Dose-comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Subjects With Hypercholesterolemia STELLAR 0065 4/24/01
A Randomized, Controlled Study of the Use of Central Venous Catheter Core Cooling and Rewarming as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction ICE-IT 7/19/02
“A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects” ESSENTIAL 11/19/01
A Randomized, Double-Blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, Slow- Release Formulation, in the Treatment of High Risk De Novo Coronary Lesions TAXUS V 1/28/03
SVG Protection In a Distal Embolic Protection Randomized Trial SPIDER 2/19/03
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-week Study to Evaluate the Efficacy and Safety of Ezetimibe 10-mg/day When Added to Ongoing Therapy with a Statin Versus Statin Therapy Alone, in Patients with Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level MK-0653 EASE 2/12/03 - 10/23/03
A Prospective, Randomized Trial Evaluating the Slow-Release Formulation TAXUS™ Paclitaxel-Eluting Coronary Stents in the Treatment of In-stent Restenosis Boston Scientific Corporation 6/13/03
C-STAARR (CardioPath™ Saphenous Vein Graft Treatment for Active Atherothrombotic Debris Removal-Randomized) Pilot Trial and Trial PTC 03046B 09/17/03 - 1/28/05
A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects ESSENTIAL 11/19/01
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Factorial Study of Metoprolol Succinate Extended-Release Tablets (Toprol-XL), Hydrochlorothiazide and their Combination in Patients with Essential Hypertension (ATTACH) 6/5/03
A Phase IV, Multicenter, Double-Blind, Randomized, Parallel Group, Dose-Response Study to Assess the Effect of Extended Release Metoprolol Succinate on Cardiac Remodeling in Symptomatic Chronic Heart Failure Patients with Left Ventricular Dysfunction (MD-CHF) 6/9/03 - 5/24/04
Rev: 4/29/2018 Page 11 of 14 Curriculum Vitae John R. Harvey, M.D.
An International Randomized Double-Blind Study Evaluating the Efficacy and Safety of Fondaparinux vs. Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-Segment Elevation MI Acute Coronary Syndromes (OASIS 5) 9/24/03
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of 200 mg. Oral Dose PG-116800 given as Sodium Salt (PG-530742) Twice Daily for 90 Days to Patients Following Acute MI with Post-Treatment Follow-Up (PREMIER) 8/20/03 - 7/28/04
A Phase III, Randomized, Double-Blind, Double Placebo-Controlled, Multicenter, Three Parallel Group Study of Enoximone Plus Extended-Release Metoprolol Succinate in Advanced Chronic Heart Failure Subjects Previously Intolerant to B-Blocker Treatment (EMPOWER) 10/8/03
Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure (EVEREST) 10/24/03
A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of Immune Modulation Therapy (Celecade ™) on Mortality and Morbidity In Patients with Chronic Heart Failure (ACCLAIM) 7/23/04
Study No. 2003056, A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (APEX-AMI) 9/3/04
Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) 7/21/04
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adult Patients Undergoing Cardiovascular Surgery (NABI-1366) 10/14/04
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients with NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels (DITPA) 12/16/04
A multi-center, single-arm study of the TAXUS Liberte’™-SR stent for the treatment of patients with de novo coronary artery lesions ATLAS 8/11/04
A Randomized, Double-Blind, Multicenter, Study Evaluating The Effects Of Eplerenone versus Placebo On Ventricular Remodeling in Patients With Left Ventricular Systolic Dysfunction (EF ≤35%) And Mild To Moderate Heart Failure (REMODEL) 2/2/05
TAXUS ATLAS DIRECT STENT Study: A multi-center, singlearm study of the TAXUS Liberté™-SR stent for the direct stenting treatment of patients with de novo coronary artery lesions 2/15/05
TAXUS ATLAS LONG LESION: A multi-center, singlearm study of the TAXUS Liberté™-SR stent for the treatment of patients with long de novo coronary artery lesions 2/15/05
TAXUS ATLAS SMALL VESSEL: A multi-center, singlearm study of the TAXUS Liberté™- SR stent for the treatment of patients with de novo coronary artery lesions in small vessels
Rev: 4/29/2018 Page 12 of 14 Curriculum Vitae John R. Harvey, M.D. 2/15/05
SYNergy between PCI with TAXUS™ and Cardiac Surgery (SYNTAX) 3/24/05
A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter, Pharmacokinetic, Pharmacodynamic and Tolerability Study of ETC-588 in Patients with Stable Atherosclerosis (ESPERION) 4/1/05
CARE (Visipaque™320 and Isovue®-370 in Cardiac Angiography in Really Impaired Patients 7/12/05 - 7/26/06
BLOCK HF - Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare effects of Coreg CR and Coreg IR on Ejection Fraction in Subjects with Stable Chronic Heart Failure COMPARE 11/16/05
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study To Examine The Effects of AC2592 Administered By Continuous Subcutaneous Infusion In Subjects With Advanced Chronic Congestive Heart Failure PROCLAIM 1/20/06
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxxTM Drug Eluting Coronary Stent System as compared to the TaxusTM Express2™ Paclitaxel-Eluting Stent in de novo Coronary Arterial Lesions ZOMAXX 1/17/06
Clinical Protocol CV185023, A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome APPRAISE 1 - 4/13/06
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi- centre, parallel-group, non-inferiority trial RE-LY 3/22/06
A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixabon, in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy SEPIA 4/11/06
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist, TOPCAT 4/21/06
PUBLICATION/ABSTRACTS:
Harvey J., Teague S., Anderson J., Voyles W., Thadani U., "Client Silent Atrial Septal Defects: An Association With Neurologic Deficits." Ann. Intern. Med. 1986:105 (5) 695-697.
Goli V., Teague S., Prasad R., Harvey J., Voyles W., Olson E., Schechter E., Thadani U., "Noninvasive Evaluation of Aortic Stenosis Severity Utilizing Doppler Ultrasound and Electrical
Rev: 4/29/2018 Page 13 of 14 Curriculum Vitae John R. Harvey, M.D. Bioimpedance." J. Amer. College of Cardiology, 1988:11 (1):1-7.
Harvey J., Wyman M., McKay R., Baim D., "Prophylactic Temporary Pacing During Diagnostic and Therapeutic Catheterization Procedures: Use of Balloon Flotation Catheters." J. Amer. College of Cardiology, 1988.
Harvey J., Anderson J., Voyles W., Olson E., Thadani U., Teague, "Silent" Atrial Septal Defect Found by Contrast Echocardiography are Highly Associated with Embolic Stroke." J. Amer. College of Cardiology, 1985:72 (III-130).
Goli V., Teague S., Prasad R., Harvey J., Voyles W., Thadani U., "A Doppler-bioimpedance Hybrid For Aortic Stenotic Area: Better Than Continuity?" Circulation, 1987:76 (VI-354).
Harvey J., Wyman M., McKay R., Baim D., "Prophylactic Temporary Pacing During Diagnostic and Therapeutic Catheterization Procedures: Use of Balloon Flotation Catheters." (submitted)
Sundram P., Harvey J., Aresty J., Lorell B., McKay R., Diver D., Safian R., Baim D., "Benefit of the "Bailout" Catheter For Emergency Bypass Surgery After Failed PTCA." (submitted)
Levine M., Cunningham M., Berman A., Harvey J., Wyman M., Sundram P., Weinstein J., Diver D. Safian R., Come P., McKay R., "Follow-up In Patients Undergoing Balloon Mitral Valvuloplasty." (submitted)
Rev: 4/29/2018 Page 14 of 14